Navigation Links
Novartis and collaborators discover novel antimalarial drug candidate
Date:9/2/2010

Singapore, September 3, 2010 Novartis announced today that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria. Major support for the project was provided by the Wellcome Trust, the Medicines for Malaria Venture (MMV), A*STAR, Singapore and the U.S. government.

Published this week in Science the findings demonstrate that the antimalarial candidate, spiroindolone NITD609, is effective against both strains of the malaria parasite, Plasmodium (P.) falciparum and P. vivax. Through a novel mechanism NITD609 rapidly clears plasmodium in a malaria mouse model and shows pharmacological properties compatible with a once-daily dosing regimen. Copies of the embargoed Science paper are available at scipak@aaas.org.

According to the World Health Organization (WHO), in 2008 there were approximately 247 million cases of malaria, causing nearly one million deaths, mostly among young children in Africa. Although malaria is preventable and curable, it is estimated that in Africa, a child dies every 45 seconds from the disease.1

"Malaria remains a scourge," said Mark Fishman, president, Novartis Institutes for BioMedical Research. "The parasite has demonstrated a frustrating ability to outwit new medicines, from quinine to today's unsettling increased tolerance to artemisinin derivatives. We are delighted that our scientists could provide this potential new malaria therapy, based on an unprecedented chemical structure and directed to a novel target."

Further regulatory pharmacological and safety evaluation is currently ongoing and, provided the outcome of these studies is favorable, the compound could progress to Phase I human trials.

A novel mechanism of action

Despite significant advances in Plasmodium genome biology, the identification and validation of new drug targets has proven challenging. In the Science paper the research team outlines how they identified a potential target by identifying mutations that decreased the parasite's sensitivity to this novel compound class.

"Using a novel Plasmodium whole-cell assay we were able to tap into the Novartis archive of 12,000 pure natural products and synthetic compounds to identify 275 compounds highly active against P. falciparum, the most prevalent and deadly form of malaria," said Novartis Institute for Tropical Disease's Bryan Yeung, project team head. "From this set all but 17 compounds were discarded for failing to meet pharmacological and efficacy standards. Of the remaining compound class, spirotetrahydro-beta-carbolines or spiroindolones have favorable physical and chemical properties for drug development as well as a mechanism of action distinct from the currently used therapies based on aminoquinolines and artemisinin derivatives."

Combating malaria- a sustainable commitment

As of June 2010, Novartis has delivered over 340 million of its antimalarial treatments without profit, to more than 60 malaria-endemic countries for public sector use, making Novartis the leading pharmaceutical partner in the fight against malaria. But Novartis does more than providing effective treatment. Since the beginning of its Malaria Initiatives program Novartis has pioneered access to medicines in the developing world through an innovative not-for-profit distribution concept, coordination of best practice sharing workshops, development of new formulations and capacity building. The program proves that increasing access is not just a matter of buying drugs and distributing them, it is about incorporating training, logistics management and other types of technical expertise to ensure long-term health impacts.


'/>"/>

Contact: Mariellen Gallagher
mariellen.gallagher@novartis.com
001-617-871-7665
Novartis Institutes for BioMedical Research
Source:Eurekalert

Related biology news :

1. Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research
2. Clemson and collaborators receive $1.1 million to improve durability of concrete infrastructure
3. K-State researcher, collaborators study virulence of pandemic H1N1 virus
4. Formula discovered for longer plant life
5. Chemical equator discovery will aid pollution mapping
6. Researchers discover that growing up too fast may mean dying young in honey bees
7. Scientists discover why a mothers high-fat diet contributes to obesity in her children
8. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
9. Groundbreaking discovery may lead to stronger antibiotics
10. Discovery of natural compounds that could slow blood vessel growth
11. Earliest animal footprints ever found -- discovered in Nevada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... USA, and CARDIFF, UK (PRWEB) , ... February ... ... international society for optics and photonics , have been named Fellows of the ... significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and ...
(Date:2/22/2017)... , Feb. 22, 2017 Scientists propose ... inflammation and organ damage in Gaucher and maybe other ... risks and lower costs than current therapies. ... Hospital Medical Center , which also included investigators from ... , report their data Feb. 22. The study was ...
(Date:2/22/2017)... Dublin - Research and Markets ... (Bio-Pesticide) Market-By Type, By Application, By End User, By Region, By ... ... Protection Market is forecasted to grow at a CAGR of 11.33% ... biological crop protection market is driven by the surging demand for ...
(Date:2/22/2017)... DIEGO , Feb. 22, 2017  Creative ... expansion of its translational research program using its ... of laboratory facilities in San Diego.  The Company ... BioLabs facility, a biotechnology incubator sponsored by the ... In November 2016, the Company obtained an ...
Breaking Biology Technology: